- Home
- WLY vs JANX Comparison
WLY vs JANX Comparison
Compare WLY & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- JANX
- Stock Information
- Founded
- WLY 1807
- JANX 2017
- Country
- WLY United States
- JANX United States
- Employees
- WLY N/A
- JANX N/A
- Industry
- WLY Books
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- JANX Health Care
- Exchange
- WLY Nasdaq
- JANX Nasdaq
- Market Cap
- WLY 2.7B
- JANX 3.0B
- IPO Year
- WLY N/A
- JANX 2021
- Fundamental
- Price
- WLY $44.42
- JANX $40.91
- Analyst Decision
- WLY
- JANX Strong Buy
- Analyst Count
- WLY 0
- JANX 11
- Target Price
- WLY N/A
- JANX $83.09
- AVG Volume (30 Days)
- WLY 406.7K
- JANX 971.4K
- Earning Date
- WLY 03-06-2025
- JANX 03-07-2025
- Dividend Yield
- WLY 3.16%
- JANX N/A
- EPS Growth
- WLY N/A
- JANX N/A
- EPS
- WLY N/A
- JANX N/A
- Revenue
- WLY $1,759,570,000.00
- JANX $13,049,000.00
- Revenue This Year
- WLY N/A
- JANX $39.66
- Revenue Next Year
- WLY $1.13
- JANX N/A
- P/E Ratio
- WLY N/A
- JANX N/A
- Revenue Growth
- WLY N/A
- JANX 54.12
- 52 Week Low
- WLY $32.50
- JANX $7.79
- 52 Week High
- WLY $53.96
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- WLY 49.46
- JANX 30.24
- Support Level
- WLY $43.07
- JANX $40.36
- Resistance Level
- WLY $43.84
- JANX $47.46
- Average True Range (ATR)
- WLY 0.87
- JANX 3.77
- MACD
- WLY 0.38
- JANX -1.46
- Stochastic Oscillator
- WLY 87.24
- JANX 4.24
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.